No abstract available.
Humans ; Liver Neoplasms* ; Liver* ; Tissue Donors*

No abstract available.
Humans

No abstract available.
Plasma Exchange* ; Plasma* ; Seoul*

No abstract available.
Erythrocytes*

No abstract available.
Plasma Exchange* ; Plasma* ; Seoul*

No abstract available.
Erythrocytes*

No abstract available.
Neurofibromatoses*

No abstract available.
Hepacivirus* ; Hepatitis C* ; Hepatitis*

BACKGROUND: Recently some countries such as U.S.A. and Canada where human immunodeficiency virus(HIV) infection is rather prevalent, included HIV-1 p24 antigen test as a routine donor blood screening. This study was performed to evaluate the advantage of additional p24 antigen testing for the prevention of transfusion-associated AIDS infection in Korea. METHODS: Blood collected from 1726 volunteer blood donors, 16 HIV-positive patients, 39 sera from 4 commercial seroconversion panels, 15 sera included in low titer performance panel were tested with HIV-1 p24 Antigen ELISA Test System(Ortho Diagnostic Systems, U.S.A.). Anti-HIV antibody was also measured in parallel employing commercial kits produced by two world-famous companies. For some sera, western blot testing was additionally done. RESULTS: False-positive rate of p24 antigen testing was 0.06%. In 2 examples from 4 seroconversion panels, the p24 antigen test detected HIV infection 1-25 days and 11-47 days earlier than anti-HIV tests. CONCLUSION: Additional p24 antigen testing was found to have a potential to reduce transfusion-associated HIV infections. Including the p24 antigen testing as a routine donor screening should be considered if the number of transfusion-associated HIV infections continues to grow in Korea.
Blood Donors ; Blotting, Western ; Canada ; Donor Selection ; Enzyme-Linked Immunosorbent Assay ; HIV Infections ; HIV-1 ; Humans* ; Korea ; Mass Screening ; Tissue Donors ; Volunteers

No abstract available.
Animals ; Isoproterenol* ; Plasma* ; Rats* ; Renin*